Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer
| Autor: | Victor I Seledtsov, Alexei A. von Delwig |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty animal diseases Clinical Biochemistry Psychological intervention chemical and pharmacologic phenomena Cancer prognosis 03 medical and health sciences 0302 clinical medicine Immune system Adoptive Cell Immunotherapy Internal medicine Neoplasms Drug Discovery medicine Humans Prospective Studies Pharmacology business.industry Cancer biochemical phenomena metabolism and nutrition medicine.disease Combined Modality Therapy 030104 developmental biology 030220 oncology & carcinogenesis bacteria Immunotherapy business |
| Zdroj: | Expert opinion on biological therapy. 21(3) |
| ISSN: | 1744-7682 |
| Popis: | The immune system is able to exert both tumor-destructive and tumor-protective functions. Immunotherapeutic technologies aim to enhance immune-based anti-tumor activity and (or) weaken tumor-protective immunity.Cancer vaccination, antibody (Ab)-mediated cytotoxicity, Ab-based checkpoint molecule inhibition, Ab-based immunostimulation, cytokine therapy, oncoviral therapy, drug-mediated immunostimulation, exovesicular therapy, anti-inflammatory therapy, neurohormonal immunorehabilitation, metabolic therapy, as well as adoptive cell immunotherapy, could be coherently used to synergize and amplify each other in achieving robust anti-cancer responses in cancer patients. Tumor-specific immunotherapy applied at early stages is capable of eliminating remaining tumor cells after surgery, thus preventing the development of minimal residual disease. Patients with advanced disease stages could benefit from combined immunotherapy, which would be aimed at providing tumor cell/mass dormancy. Traditional therapeutic anti-cancer interventions (chemoradiotherapy, hyperthermia, anti-hormonal therapy) could significantly enhance tumor sensitivity to anti-cancer immunotherapy. It is important that lower-dose (metronomic) chemotherapy regimens, which are well-tolerated by normal cells, could advance immune-mediated control over tumor growth.We envisage that combined immunotherapy regimens in the context of traditional treatment could become the mainstream modality for treating cancers in all phases of the tumorigenesis. The effectiveness of the anti-cancer treatment could be monitored by the following blood parameters: C-reactive protein, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|